Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRELLA Trial of Isatuximab Combinations in Relapsed or Refractory Multiple Myeloma
NCT04643002Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2021
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of SAR439459, belantamab mafodotin, pegenzileukin, belumosudil, evorpacept in multiple myeloma (MM), sponsored by Sanofi. Started Jan 2021; status: recruiting.
02
Drugs
SAR439459belantamab mafodotinpegenzileukinbelumosudilevorpacept
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04643002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643002.